Mesoblast Limited (ASX:MSB – Get Free Report) insider Gregory George bought 74,621 shares of the stock in a transaction dated Monday, March 10th. The stock was acquired at an average price of A$12.88 ($8.10) per share, with a total value of A$961,118.48 ($604,477.03).
Gregory George also recently made the following trade(s):
- On Monday, March 3rd, Gregory George acquired 5,034,129 shares of Mesoblast stock. The shares were bought at an average cost of A$2.95 ($1.85) per share, for a total transaction of A$14,830,544.03 ($9,327,386.18).
Mesoblast Price Performance
The company has a market capitalization of $2.32 billion, a price-to-earnings ratio of -23.29, a PEG ratio of 9.56 and a beta of 2.38. The company has a current ratio of 1.18, a quick ratio of 1.82 and a debt-to-equity ratio of 24.76.
About Mesoblast
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Stories
- Five stocks we like better than Mesoblast
- How to Use the MarketBeat Excel Dividend Calculator
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- How to Short Nasdaq: An Easy-to-Follow Guide
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.
